The National Institute for Health and Care Excellence has recommended linzagolix (marketed as Yselty) for moderate to severe symptoms of uterine fibroids, an option that could benefit up to 30 000 adults in England and Wales.1
In final guidance, published on 14 August, NICE said that linzagolix can be offered …
